Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
B-Cell Lymphoma
Research in the area of B-cell lymphoma reported from Y. Terui and colleagues
May 26th, 2009
According to a study from Tokyo, Japan, "Rituximab is commonly incorporated into CD20-positive B-cell lymphoma therapy to improve response and prognosis, With increasing use, resistance to rituximab is a continuing concern, but CD20 mutation as a cause of resistance has not previously been reported. Freshly collected lymphoma cells from 50 patients with previously untreated or relapsed/resistant non-Hodgkin's B-cell lymphomas (diffuse large B cell, n=22; follicular, n=7; mucosa associated lymphoid tissue, n=16; chronic lymphocytic leukemia, n=2; small lymphocytic lymphoma, n=1; lymphoplasmacytic, n=1; mantle cell lymphoma, n=1) were assessed for CD20 expression by flow cytometry, and CD20...
Source: Cancer Weekly (2009-05-26)
|
